- Home
- FBIOP vs THRY Comparison
FBIOP vs THRY Comparison
Compare FBIOP & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- THRY
- Stock Information
- Founded
- FBIOP N/A
- THRY 2012
- Country
- FBIOP United States
- THRY United States
- Employees
- FBIOP 186
- THRY N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- THRY Industrial Machinery/Components
- Sector
- FBIOP Health Care
- THRY Industrials
- Exchange
- FBIOP Nasdaq
- THRY Nasdaq
- Market Cap
- FBIOP N/A
- THRY N/A
- IPO Year
- FBIOP N/A
- THRY 2020
- Fundamental
- Price
- FBIOP $5.75
- THRY $13.11
- Analyst Decision
- FBIOP
- THRY Strong Buy
- Analyst Count
- FBIOP 0
- THRY 4
- Target Price
- FBIOP N/A
- THRY $22.50
- AVG Volume (30 Days)
- FBIOP N/A
- THRY 433.0K
- Earning Date
- FBIOP N/A
- THRY 05-01-2025
- Dividend Yield
- FBIOP N/A
- THRY N/A
- EPS Growth
- FBIOP N/A
- THRY N/A
- EPS
- FBIOP N/A
- THRY N/A
- Revenue
- FBIOP N/A
- THRY $824,156,000.00
- Revenue This Year
- FBIOP N/A
- THRY N/A
- Revenue Next Year
- FBIOP N/A
- THRY N/A
- P/E Ratio
- FBIOP N/A
- THRY N/A
- Revenue Growth
- FBIOP N/A
- THRY N/A
- 52 Week Low
- FBIOP N/A
- THRY $12.47
- 52 Week High
- FBIOP N/A
- THRY $26.42
- Technical
- Relative Strength Index (RSI)
- FBIOP 35.47
- THRY 25.80
- Support Level
- FBIOP $5.50
- THRY $12.47
- Resistance Level
- FBIOP $6.74
- THRY $15.60
- Average True Range (ATR)
- FBIOP 0.27
- THRY 0.74
- MACD
- FBIOP -0.08
- THRY -0.19
- Stochastic Oscillator
- FBIOP 20.00
- THRY 19.57
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.